Plain-English translation of NCT05495152 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing a medication called to see if it can help prevent esophageal cancer from coming back after surgery. Some patients with esophageal squamous cell carcinoma remain at high risk for recurrence even after chemotherapy and surgery. The study will compare patients who receive this medication after their surgery to patients who receive only routine follow-up care.
Right now, doctors don't have a clear best treatment to give after surgery for patients whose cancer hasn't completely disappeared or who have unexpected lymph node involvement. This trial exists to find out whether the medication can reduce the chance of cancer returning in these high-risk patients.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will be randomly assigned to one of two groups. One group will receive 17 intravenous infusions of the medication over about one year, with each infusion given every three weeks in the hospital or clinic. The other group will simply have routine follow-up appointments without the medication. Throughout the trial, you will have regular blood tests and doctor visits to monitor your health and watch for any signs of cancer returning.
AI-generated summary from trial data · Jun 19, 2026 · Not medical advice
China